|1||Pent up Consumer Demand! Consumers seek personalized nutrition and an edge from their DNA data.|
|2||Subscription sales model = Revenue predictability, more consumer Engagement, greater Margins|
|3||COVID-19-fueled hyper-growth of online supplement spend expected to accelerate during fall/winter.|
|4||Customizable EQUIP™ supplement and DNA-informed GeneLytics™ Nutrigenomics Reports ✔ Market-Ready.|
|5||The global Personalized Nutrition and Wellness Market set to reach $130B in five years.|
|6||The supplement industry e-comm. growth rate has skyrocketed; expected to grow by 61.4% in 2020.|
|7||Non-pill formats now account for 52% of supplement sales across all channels.|
|8||Diverse | Experienced Leadership Team. Exceptional credentials: CPG, D2C, subscription, Marketing|
At Takezo, our Mission is To be the most effective, inspirational, and trusted personal performance brand in the world. We want You on our team and to own part of Takezo. Together we will lead a revolution in health and wellness and as Investors, well, there's that share of $67B…
Our video (above) provides a great overview of Takezo by our Co-Founder and CEO, Reid and more detail follows in our Story (below). Meeting is believing and we would love to speak with you about owning part of Takezo. Here is a link to our calendar. Just pick a convenient time for you and we'll see you then. Meet with Takezo
Hit that INVEST button!
Achieving & Maintaining optimum health & wellness requires proper nutrition & lifestyle. Every person has unique goals, dietary preferences, as well as unique genetic and biologic markers. Consumers are seeking personalized nutrition:
✔ Addresses their Uniqueness
✔ Is Configurable on their terms
✔ Updates as frequently as needed
✔ Includes convenient personal Support they deserve
According to MIT, by the close of 2020, more than 100 million people globally will have used one of the several available services to obtain their DNA profile. One might conclude from the recent sale of Ancestry.com for over $700 million, that business is indeed good in that space. Takezo has the capability to help our consumers realize more value from their DNA information through our GeneLytics™ service.
► Uses consumers' raw DNA data file
► Reveals to our consumers, implications regarding nutrition and wellness in several insightful reports.
► Takezo uses GeneLytics™ to make recommendations and to inform EQUIP™ Personalization profiles.
Historically, the presumption has been that everyone absorbs and metabolizes nutrients similarly. Differences in daily requirements have been based on age, gender, or pregnancy/breastfeeding status. Current knowledge tells us that is no longer an appropriate approach to nutrition. The Predict1 study found that we ALL process nutritional components in a unique manner to each other, there is no such thing as "AVERAGE" when it comes to nutrition. Astonishingly even identical twins react completely differently to the same nutrition. (Nature Medicine June 2020)
EQUIP™ Personalized Daily Supplements are ready-to-eat and delicious; more of a snack and definitely not a pill! Our consumer can configure EQUIP™ to their unique needs by taking advantage of over 87 billion potential ingredient combinations. Consumers can also re-configure Equip™ as their needs change. If a consumer has their 23&ME or Ancestry DNA results, all they have to do is upload them in four easy steps to get their Genelytics™ results. The related nutrigenomics data therein can be used to get an even more precise configuration.
Genelytics™ is included with every EQUIP™ subscription, and in addition to their nutrigenomics discoveries, they also receive 5 other useful reports providing 140+ wellness traits, helping Takezo consumers to build on their strengths, adjust for their weaknesses, and perform at their best.
We have identified a large target population of consumers. Our core consumers like to plant flags, whether it is training to finish that charity walk, lower their handicap, excel at e-sports, or be the Spartan Race Global Champion, Takezo is on that journey with each consumer.
From the beginning, our goal has been to build an investment-ready company. Takezo is ready to go with our EQUIP™ product and GeneLytics™ service positioned to be in-market generating revenue within a few weeks of funding. Takezo pro-forma financials reflect a business model targeting growth rates to not only facilitate further funding rounds but also with an eye to a solid exit that rewards all investors.
The Takezo story began with one of our co-founders and current CEO Reid A. Block. Reid was adopted at birth (by two amazing people, Robert and Sharon) and was naturally curious about his biological ancestry and any genetic health concerns that might be lurking. As a lifelong competitive athlete, Reid was also looking for what nutrition was right or bad for him, and if he had any genetic disadvantages that he needed to adjust for.
Reid took the 23&Me at-home DNA test and his comprehensive health and wellness reports from Dr. Rhonda Patrick’s ‘Found My Fitness’. He had nothing notable to worry about on the disease risk spectrum but was most curious about the nutrigenomic insights, that included:
⚠ Supplementing with Vitamin E is likely harmful to him
🧬 Genetic vitamin d deficiency
β ~32% reduced conversion of beta-carotene into retinol
Ω ~26.7% poorer conversion of ala into omega-3 epa
Additionally, Reid participated in the comprehensive Predict 2 study. Reid learned that while we are all unique we are vastly more so at the nutrigenomic level and that DNA can inform you of your super nutrients and those you should avoid. The Predict 2 study provided Reid with:
🍽 A personalized list of what foods are best for him
🧫 Gut health from his microbiome test. (his gut health was pretty bad)
🎯 Score for specific foods based on his blood sugar stress/gut health impact (microbiome)/avoidance of food-driven inflammation/blood fat stress.
Reid was now swimming in his own nutrigenomics data and started to look for nutritional solutions that could use that data and turn it into nutritional solutions to supplement his personal dietary and performance needs. To his surprise, there were few solutions, other than some vitamin pill packs. Surprised by a remarkable lack of one-stop personalized nutritional options, the serial entrepreneur in Reid saw the beginning of an opportunity. As he began to explore the personalized nutrition space Reid found there was a massive opportunity based on timing, scalability, market size, and gaps, amongst other things. Reid set out to launch Takezō and began to assemble a team of leaders, directors, advisors, professional services, and industry partners to deliver personalized precision nutrition and technologies that enable their consumers to perform at their best.
Takezo sees an opportunity to create off-the-shelf products based on frequent EQUIP™ personalization profiles and make these products convenient and available through multiple channels. FOCUS™ is the first pre-configured product developed based insights gleaned from EQUIP R&D& frequent personalization profiles.
The value to our consumers:
➕ Ready-made convenience and serving sizes.
➕ Omnichannel purchase options (Takezo direct and E-tailers)
➕ Attractive price per serving, and available in single-serve or multi-serve options.
The value to Takezo:
✔ Increased gross margins
✔ Improved supply chain planning
✔ Market intelligence
✔ Increased consumer retention.
In moving ahead with FOCUS™ development, we have pre-loaded our 2021 revenue plan and will be ready to launch as we achieve a cadence with our early EQUIP™ subscriber base.
Funds raised on WeFunder will be used for final system integrations with supply chain partners and the materials and data needed to launch Equip™, Genelytics™, and Focus™ into the market. But you already know that. What you do not know is that Takezo has recently engaged both engineering and R&D resources in the development of proprietary technology that will revolutionize the personalization experience for our consumers and the range of nutritional products available to them.
More detail will be made available to investors in the coming weeks and we want you to be part of that!
Invest with Takezo now - BE part of the team - BETAKEZO!
Takezo LLC has financial statements ending December 31 2019. Our cash in hand is $216, as of April 2020. Over the three months prior, revenues averaged $0/month, cost of goods sold has averaged $0/month, and operational expenses have averaged $2,510/month.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this offering. Some of the information contained in this discussion and analysis, including information regarding the strategy and plans for our business, includes forward-looking statements that involve risks and uncertainties. You should review the "Risk Factors" section for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.
Takezō is dedicated to your comprehensive wellness and personal performance. We offer personalized & ready-made premium supplements, designed to help you function at your best. To help you achieve your mission, we provide personal performance technology, and the support of a like minded Tribe.
Our mantra is “For you – By Us”
Equip FIT has roughly 87 billion potential identified ingredient combinations, and hope to grow that to a few trillion. Our RTM includes Focus, Energy, Rest, & Revive.
In five years, we want to be the #1 provider of personalized nutritional solutions in the world, although this cannot be guaranteed.
Given the Company’s limited operating history, the Company cannot reliably estimate how much revenue it will receive in the future, if any.
Takezo LLC was organized in the State of Delaware in May 2018. It was the intent of management from inception to attract recognized subject matter leaders for each of the business areas in which we seek to establish unique competitive advantage. Additionally it has been a Takezo guiding principle to build out consumer and market-ready solutions prior to operational launch and thus be in a position to realize revenue quickly, post funding. Key leaders of Takezo have invested considerable knowledge capital to self-fund Takezo to prepare for a rapid path to revenue for investors (we hope). To this end, we believe Takezo is poised for that rapid launch. The Takezo Focus product is purchase-order ready with approved packaging. Equip FIT has final technology & process configuration steps remaining with our co-manufacturer, the timeline of which has been impacted by COVID. Dynamics in the economy may allow Takezo initiate an introduction of minimally configurable Equip coincident with this offering
Since then, we have:
Historical Results of Operations
Our company was organized in May 2018 and has limited operations upon which prospective investors may base an evaluation of its performance.
Liquidity & Capital Resources
After the conclusion of this Offering, should we hit our minimum funding target, our projected runway is 4 months before we need to raise further capital.
We plan to use the proceeds as set forth in this Form C under "Use of Funds". We don’t have any other sources of capital in the immediate future.
We will likely require additional financing in excess of the proceeds from the Offering in order to perform operations over the lifetime of the Company. We plan to raise capital in 2 months. Except as otherwise described in this Form C, we do not have additional sources of capital other than the proceeds from the offering. Because of the complexities and uncertainties in establishing a new business strategy, it is not possible to adequately project whether the proceeds of this offering will be sufficient to enable us to implement our strategy. This complexity and uncertainty will be increased if less than the maximum amount of securities offered in this offering is sold. The Company intends to raise additional capital in the future from investors. Although capital may be available for early-stage companies, there is no guarantee that the Company will receive any investments from investors.
Runway & Short/Mid Term Expenses
Takezo LLC cash in hand is $216, as of April 2020. Over the last three months, revenues have averaged $0/month, cost of goods sold has averaged $0/month, and operational expenses have averaged $2,510/month, for an average burn rate of $2,510 per month. Our intent is to be profitable in 18 months. The founding team can infuse capital to cover short-term operations.
No material changes or trends in finances or operations have occurred since the date of the financials provided.
Based on the current financial forecast, we expect revenues to approach $185000 on roughly $300000 of expenses by the 3 month mark and total $900000 on $1 million of expenses 6 months out. This forecast assumes we achieve our mid-tier funding goal of $350k. Projections cannot be guaranteed.
$50k minimum raise will enable the maturation of a brand development marketing and advertising program, sales launch of our DNA-based health and nutrition reports, launch of Takezo Equip, and pre-orders of Takezo Focus. We forecast that this level of funding would help us achieve revenue at an annualized rate of $17k/month.
To-date, Takezo LLC has been self-funded. Once full operations are funded, Management plans to secure an operating line of credit to support cash availability as the business develops stronger operating cash flow. Our current 5-yr. business plan includes an operating line utilization of no more than 60% of $100000 availability.
Takezo LLC may never receive a future equity financing or elect to convert the Securities upon such future financing. In addition, the Company may never undergo a liquidity event such as a sale of the Company or an IPO. If neither the conversion of the Securities nor a liquidity event occurs, the Purchasers could be left holding the Securities in perpetuity. The Securities have numerous transfer restrictions and will likely be highly illiquid, with no secondary market on which to sell them. The Securities are not equity interests, have no ownership rights, have no rights to the Company’s assets or profits and have no voting rights or ability to direct the Company or its actions.
We are a Start-up company without prior revenues or sales.
Our business model, including sales and growth forecasts are unproven. While the model assumptions are informed by the considerable business experience of our management team and industry advisors, actual results will likely be different from those predicted by the model. Our financial results will differ from those forecasted and any valuation of Takezo LLC at this stage is difficult to assess.
Small management team.
Supply chain risks.
Takezo depends on a network of manufacturing/co-packer and fulfillment organizations to execute our business. The inability of any of these partner organizations to follow through on their commitment would require us to replace them with another partner. As a nutrition business, we carry certain food safety risks. We rely on the practices and certifications maintained by our supply chain partners to mitigate these safety risks.
Use of proceeds in this offering.
We are a food company.
As a food and supplement company we face certain risks related to both food safety and regulatory practices throughout our supply chain. We mitigate these risks to the business through management vigilance and peerless legal and risk management advisor firms. Importantly, we seek to protect our consumers by partnering with recognized, certified and equally minded supply chain partner firms. Additionally, as a food company we face unforeseen risk associated with unknown and unpredictable use of product by the consumer.
These are not all the risks.
We have highlighted here what we as the management team see as the main risks related to this offering. This is not a comprehensive list of all risks. For more risks associated with this offering, see the Offering Document and see the Wefunder FAQ page at https://help.wefunder.com/
Kim Terry, Patrick Connors, Bryan Emmerson and Karen Vaughn are part-time officers. As such, it is likely that the company will not make the same progress as it would if that were not the case.
Already have a Wefunder account? Login
Don't have a Wefunder account? Signup